text: Why You Will NEVER Become A Man Leigh (LoGun) Featured, Inner Game 26 Comments How long will it take you to become a Man? And I'm not just talking about an adult male here. Age is not a factor. I mean that strong, powerful, authentic, courageous Man that women are drawn to. A month? A year? Maybe 10 years? Well, I'm sorry to be the one to disappoint you, but if you're giving yourself even a week, you may as well be giving yourself 100 years because you'll never become a Man. Ever. Because if you're giving yourself any amount of time before you become the authentic, committed, courageous Man that you know you can be, then somewhere in your mind, you have to be thinking that there's something you need to collect / achieve / do before you become a Man. That there's some arbitrary set of goals to achieve before you can bestow that title upon yourself. But a Man isn't defined by the number of objects he's collected or the amount of activities he's done. There's no specific set of things he has to purchase, do, or achieve to become a Man. A Man is defined by how he lives his life in this present moment and that can only happen in this present moment. You can't 'become' a Man. You are either being a Man or you are not being a Man. You are either living your life with integrity, authenticity, dedication, independence, and courage, in this present moment or you are not. You're either pushing through challenges with determination and commitment, or you are not. You're either deeply aware of where you're going and what you believe to be true in your heart in this present moment, or you are not. There's nowhere to go, nothing to achieve, nothing to collect, nothing to create to become the kind of Man that women naturally adore. There is only: how you're choosing to live your life in this present moment? Look around you. Look at the walls that surround you, the desk you're sitting at, the clothes you're wearing, look at everything that exists in this very moment and ask yourself: How am I going to live my life in this very moment? And then once this very moment is done, ask yourself again: How am I going to live my life in this very moment? And then once you've finished with this easy moment, when there are no challenges to face and no hurdles to overcome and you're finally standing toe-to-toe with the tough decisions you usually run from, where you have to put your morals, beliefs, and courage to the test, ask yourself: How am I going to live my life in this very moment? And not 'How do I want to' but the very real, present moment, committed version: 'How WILL I live my life in this present moment?' Because if you're reading this, and you're wondering why women aren't drawn to you, and why sometimes things feel so challenging it hurts, and why sometimes you feel so alone that you want to cry, it's because you've been making a different decision in the present moment. You've been choosing, to be weak, you're choosing to be needy, you're choosing to be dependent, and you're choosing to be clingy, in this present moment. You've been choosing to run from your barriers, you've been choosing to hide from challenges, in this present moment. You've been choosing to live someone else's version of the ideal life rather than passionately pursuing your dreams, in this present moment. There is no such thing as 'becoming' a Man because there's nothing to 'become'. There is either being a Man or not being a Man. And whether or not you're being a Man is determined by the decision of how you will live your life in the ever evolving present moment. It's not a level or endpoint defined by the amount of trophies you can collect or the notches on your belt. Being a Man is a way of life. This is why your journey will never be done. This is why you'll never be finished. You will never have enough cars or slept with enough women or have enough money in your bank account to become a Man, and you will never be able to relax knowing that now, everything is complete. You will have to make the decision, the tough decision, in every present moment for the rest of your life. You can choose to live your life with integrity, honour, and courage, and be the kind of Man you know you can be for 30 years, and then you can decide to be dependent and needy and all of a sudden, you're back at square one again. There is no end point because the only time your present moment will ever finish is when you're dead and buried. So, as you move forward for the rest of the day, I want you to ask yourself one question: How am I going to live my life in this present moment? Become consciously aware, in the present moment, of what you're doing and how you're choosing to live your life. When you see all the moments where you choose weakness, fear, and dependence, make a new choice. Choose strength. Choose authenticity. Choose courage. Choose to take responsibility for your life. Choose to become the Man of your dreams. And then, when that moment is over, make that decision again. And then, when that moment is over, make that decision again. And then, when that moment is over, make that decision again. And then, when that moment is over, make that decision again. Because that is the ONLY way to EVER be a Man. Leigh P.S. If you want to understand more about why you're making the decisions you're making and what you need to do to change it, download your free copy of Seduction Community Sucks from directly below. Join over 25,000 subcribersDownload your FREE copy of Seduction Community Sucks now and get in-field videos, subscriber-only articles, and exclusive podcasts delivered directly to your inbox If you're ready to become the kind of Man that attracts confident and in-demand women without trying, then I have a gift to start you on that journey. Seduction Community Sucks is your 159 page kick-start to becoming the kind of Man that makes women go weak at the knees. Get your FREE copy, as well as access to other subscriber-only articles, podcasts, and video footage, now. Get your FREE ebook, hidden articles, in-field videos, and exclusive podcasts here: 26 Responses José Jara August 4, 2012 So hard, so true, thanks for the point of view my friend!!! Reply Breathe August 5, 2012 This is one of the simplest, yet most profound and important realizations. Reply Jammer August 6, 2012 Tomorrow I'll do it. Right now I want to sit in my room and sulk. Reply Zach August 7, 2012 Best article on the site. Reply Peter May 23, 2013 Best article on the internet. Reply Trevor September 3, 2012 I love this article. I read it every other day. I really like when you call the stuff we collect, garbage. Haha! I had a laugh and had to share it with my friend. So very true. Supremely written. Thank you Reply Leigh (LoGun) September 4, 2012 I glad to hear it mate. It's nice to know that guys are getting value from the articles. Reply Wesley September 30, 2012 Thank you for those words! Reply ron November 8, 2012 This is profound. Reply Leigh (LoGun) November 8, 2012 I'm glad you enjoyed it mate. Now, and here's the fun part, what are you going to do with it? Reply ron November 8, 2012 It was 12 AM when I read it. I got my ass up, stopped procrastinating and starting cleaning up the house, something I want to do but avoid doing. I've done everything I wanted to do, and now when I wake up tomorrow I'm going to continue this. I have a shit load of fears through out the day that I can have fun with. It's time to be aware of them and take charge. Typing that sentence out just made me feel like I have a knot in my stomach. I'm always fearing something, and I'm sick of it. I'm sick of letting it stop me from being a man. It's hard to explain, but the fears feel so damn strong, almost overpowering. But I guess that could just be me being weak. It's always the same fear, the fear of socializing. I don't even know if it's the fear of socializing. I honestly don't know where it comes from or what I'm even fearing. All I know is that when I want to speak, I feel fear. I always second guess what I want to say. This is in general, with everyone. I'm sick of this shit, so I'm done with it. I want to take action now but there's one thing on my mind: When I want to say something, and I feel fear and stop, should I say what I want to say anyway? See, right now I'm having the fear of seeming unnatural if I do that. My mind is now telling me I'm not going to know what to say if I seem unnatural and they'll think I'm weird because of it. Fear after fear. It's incredible! I want to MAN the fuck up right now! Reply Leigh (LoGun) November 8, 2012 Brilliant mate. I'm glad to hear. If you keep pushing forward, I know you'll get there. Reply Peter May 23, 2013 It was a revelation. Reply Peter May 23, 2013 I read this article and Rudyard Kipling's "If" every other day. Reply Leigh (LoGun) May 23, 2013 It's a beautiful poem. I've read it a couple of times now and I always come back to it. Great to hear you enjoyed the article. Reply Andres Casarrubias September 18, 2013 Hi ! This is an awesome article, but raises some questions in my head … You see sometimes through the day I see this beautiful or attractive girl that catches my attention, but something happens … I don't think it's fear anymore or anxiety I mean those emotions are still there but I can now overcome them and continue … I have read Endgame but I still don't understand this, By reading this article I found in myself the motivation needed to take action, since there's no other way, but back to the girl, I see that girl and I guess approaching her it's the though choice right ? I have done that before and something feels weird like no matter what I say I'm still trying to get something from her and since I'm not going to say "Hey can you respond to me nicely so i can feel good about myself for a while ? Oh and have dome sex with me ? Thanks ! 🙂 … Haha well i could but that's not going to get me very far … So what's the though choice ? Approaching her and making her responsible for how i feel ? Or not approaching and take control of how i feel ? . P.S. If is the second choice how would that be ? Awesome work with the site !! Really really thank you ! 😀 P Reply Leigh (LoGun) September 18, 2013 What about choice three: living the kind of life that means your experience isn't dictated by how other people respond to you? Reply Andres Casarrubias September 19, 2013 Oh ! you know it's funny i have read Endgame and i think that most of the articles in AI and till now i come to realise that it takes time at least for me to realise this kinf of stuff, maybe that is what "Turn Up the Volume" means, but i think the biggest change i've noticed is that I now realise that it's just a matter of choice, of every day taking a conscious choice. But to do that you first have to know what is it that you want … what my idea of my perfect world is … I know i have a long way to go, and many things to realise, do you have any advice ? Jammer September 19, 2013 If she likes you and you have sex, great. If she doesn't, still great, because someone else already is. LoGun is right on this one. Reply John March 30, 2015 Good job, the ebook is marvellous. I have been searching weeks in order to find something else than "the Mystery" and "PUA methods", as they seem too shallow and temporary. Thanks again. Reply Leigh March 30, 2015 Glad you're getting value from it mate. Reply Shaun wall July 17, 2015 I really loved this article. Where I have confusion is that if "I do what I want when I want, women will just want to be around me." I don't want to come off demanding or self centered. But I also don't want to be unconfident and passive. I'm missing th middle ground here. Reply Nickolaidas April 24, 2016 Basically, as I read and read and read articles about this website, I don't really think I need to read any more. Basically, the authors and the articles say four things (about men): A) The less fucks you give about the world, the manlier you become. B) The more activities of daily life you perform on your own, the manlier you become. C) The more you do what makes you feel good and what feels rewarding (for you), the manlier you become. D) The less you let a woman influence your thoughts and actions, the more she admires you for it. And the manlier you become. I think that's about it. Reply Akshay September 1, 2016 "This is why your journey will never be done. This is why you'll never be finished." Loved the article Leigh, I couldn't stop my hands from clicking the share button. Very Insightful knowledge. Thanks a lot 🙂 Reply Andrew C. June 6, 2017 The world had worn me down. This has re-ignited the fire in my belly that i used to have. I'd always rejected that PUA stuff that my friends would tell me about. Even so, it crept into my consciousness just enough to mess sh** up. Then i found "Her" a month or two ago. (and you know the rest) A little while ago i began Googling that stuff to see what she might think i thought. [It's an uphill battle to resist the PUA tricks. and i needed to know what i was resisting. But i had nothing to lean on, nothing proactive.] So the tricks crept in and f***** up my thinking. Then i found Attraction Inistitute, and this stuff, and felt new strength return. I'm grateful for all you guys have done. It's not the validation i was looking for. It's better. It's reinforcement of the fact that there is no "Map", no fate but what we make. Thank you. Reply Willis Stack July 2, 2017 We don't need to seduce we simply need to be real and up front Reply Leave a Reply Cancel Reply Your email address will not be published.CommentName* Email* Website Notify me of followup comments via e-mail. You can also subscribe without commenting.


text:
Jesus of the (Original) Apostles
- Who is JESUS in the 1st century? "JESUS is the TRUTH, the WAY, and the LIFE".
- With the different identities of JESUS being peddled in the pulpits and religious rallies today, Christianity has become a "market place" for truths and ways to eternal life.
- How and where can we find, and who can tell us the "teachings of the Apostles about Jesus?"
Sep 12, 1995
Audio-visual/question-answer/articles are available at YouTube.
|Main Articles
|The Virtue of 'Babes' In Christ
|2005-11-20 03:31:34

subset: commoncrawl


text:
Results 1 to 4 of 4
Thread: the 18 (eighteen) pack
01-14-2003, 09:17 PM #1Senior Member
- Join Date
- Jul 2001
- Location
- east lansing, michigan
- Posts
- 1,558
okay, this could fit into the beer section as well.
what is the deal with the 18 pack? i know that michelob light started to use it because of the whole 18 holes thing...
with beer, AB does a lot of 18 pack cans, and 20 pack bottles. i've also seen 20 packs and 24 pack bottles on the shelves at the same time.
with pop, there's the 18pack cans which are never at a huge discount price. sometimes, the 12packs are a better deal for christs sakes.
why bother making the 18 pack for pop? i don't get it. with beer, that's 9 beers a man, not a bad ratio. but with pop, i don't understand. someone help a man out.
right now, in my beer wharehouse, we have the following odd packs:
miller :
30 pack cans of best/best light, high life/high life light.
24 pack cubes of lite, mgd/mgd light.
18 pack bottles of lite, mgd/mgd lite
18 pack bottles blue/blue light
18 pack cans of molson ice
18 pack bottles of canadian/canadian light.
rolling rock 18 pack cans as well.
why freaking bother? does anything besides the 30packs move product more?woot woot
01-15-2003, 12:09 AM #2Senior Member
- Join Date
- Jul 2001
- Location
- east lansing, michigan
- Posts
- 1,558
i just saw bud/bud light 18 pack bottles.
another 18 pack to add to the list.
what does coke make? coke diet coke, lem, sprite, diet cf coke, nestea?
anymore?woot woot
We had 18 pakcs of Coke, Caff. Free, and Diet Coke a few months back but they seem to have dissapreared.<b>Hey Pepsi, Shasta called, they want their lemon-lime back.</b>
I think we had Coke, CF Coke, Diet, CF Diet, Sprite, Seagram's and Nestea in 18 packs. They don't sell worth a crap, except when they put them at a good price.
We had a promotion with Wally World this summer, and we sold quite a few. Safeway (we only have one of their stores in our sales territory) also ran a sale with them about a month or so ago.. But we had to have them specially produced the morning of the first day of that 3-day sale, and then they were driven up to our warehouse from Baltimore (about an hour's drive). Otherwise, we don't bother to sell them.


text:
A few weeks ago, our area felt the effects of an earthquake whose epicenter was just off the inland coast of Southern Vancouver Island. Every year our staffs and students practice the 'duck and cover' procedure followed by an evacuation of the building. Yet when this one struck outside of school hours, I remained on my couch wondering what had happened. I did not duck and cover, even though I have practiced this procedure every year for over 21 years!
Perhaps it is the infrequent nature of earthquakes that we physically experience that causes us to hesitate. We wonder if it is an explosion, or a large truck passing by before hitting Google to see what happened. The telltale signs of a fire are easy to identify as are flooding, and power outages. The windstorms of November pointed out some gaps in the School Emergency Preparedness Guide in dealing with some of the calamities that can accost our worksites.
The School Emergency Preparedness Guide sets out the protocols for dealing with emergencies that may best the workplace. From Lockdowns to Earthquakes, procedures and protocols are identified. Your school will also have handbooks describing the procedures to follow in the event of one of these emergencies. Procedures change as well, so it is a good document to review by Joint Occupational Health and Safety committees. For instance, many sites still have search and rescue teams to go through the school once students have been evacuated in an earthquake scenario. Yet, that is no longer required for safety reasons. Only trained First Responders should enter a building after an earthquake. How many of you are still doing that job?
Maybe we wont react exactly as we are supposed to in an emergency situation, but we can be prepared. I encourage Health and Safety reps to check out the School Emergency Preparedness Guide to ensure your school is practicing the proper protocols. You can find the document on the Staff Portal at the District website. It is under Human Resources/Health and Safety page.
As for the gaps identified from the windstorms, the District Occupational Health and Safety committee is working to include those in the Guide as soon as possible.
Be Safe,


text:
Maid Service
Consider a house cleaning service
In today's hectic world, finding time to complete chores can be challenging. Using a professional maid service provides an opportunity to get help with domestic workloads and office cleaning, allowing you to add vital relaxation time to your busy schedule. However, little time will be saved if the chosen office or house cleaning service proves unreliable. Finding the best professional cleaning services for a particular business or household can be a lengthy process.
Agency Advantages
One of the advantages of hiring a residential cleaning service through a reputable agency is that the research and investigation has already been completed. Background checks of employees have been performed and referrals have been investigated. Choosing a maid service from a classified ad listing may be risky, unless references are thoroughly checked and a level of confidence is established. If language barriers make communication difficult, misunderstandings regarding service expectations and payment may occur. By hiring house cleaning services through an agency, these issues are clearly dealt with and pre-screened maids are provided.
Another clear advantage of selecting a housekeeping service from an agency involves the legal liability of the service's domestic employees. An agency provides the protection of ensuring that proper visas and work permits are already in place. Employee benefits and payroll accounting are both handled through the agency. All the paperwork is performed by agency personnel, relieving the end client of the burden. Errors and liability issues are also controlled so that maid service can be provided without leaving the homeowner to worry about extensive payroll accounting.
Professional Maid Services
Anyone using maid services wants to feel confident that their home is protected from theft and damage. A residential cleaning service agency locates employees with proven housekeeping experience and a record of reliable service. Reports of theft or significant damage to the household are immediately reported to the agency and tracked to the responsible employee. An individual who hires a maid service independently may not have recourse if such an issue arises.
When we leave our homes to the care of others, we want reassurance that the housekeeping maid services are trustworthy. Establishing a good relationship with a housekeeper is important. An agency can provide a preferred worker or a backup person if needed. If a problem occurs, the agency resolves the issue, relieving the client of awkward dismissal proceedings.
Choosing a residential cleaning service through an agency means peace of mind. Reduced risk and reliable housekeeping services make more leisure time an attainable reality.
|Write A Comment


text:
Detente through art? Why not? Great works of art transcend political boundaries.
That`s the philosophy behind a remarkable collaborative effort between an Eastern European and an American museum, making possible an exhibition of art treasures never before seen in the United States. Drawings by Albrecht Durer, Leonardo da Vinci, Raphael Sanzio, Jean Antoine Watteau and Vincent Van Gogh, among others, that have never before traveled outside of Hungary, will be included in the 100 drawings from the Budapest Museum of Fine Arts. The exhibition will include the works of 86 artists working from the 15th century to the late 19th century.
The drawings will go on view May 12 through July 14 at the National Gallery of Art, Washington, D.C.
The exhibition also represents the largest number of works from Budapest ever loaned as a group. The selection of master drawings reveals the breadth of the Budapest graphics and emphasizes the early Italian, German and Netherlandish schools, which are rarely seen in American collections. Major French 19th century drawings are included as well.
The Budapest Museum of Fine Arts is the largest public museum of European art in Hungary and encompasses all areas of art history (except the decorative arts) from classical Greek art to the 20th century. The museum`s drawing and print cabinets, considered to be among the best in the world, contain more than 90,000 prints and some 8,000 drawings. Forming the collection`s nucleus was the Esterhazy bequest, one of the richest private holdings of drawings ever donated to a museum.
Three superb sheets by the German Albrecht Durer (1471-1528) have been chosen for the exhibit. Lancer on Horseback (1502), a vigorously animated composition, reflects Durer`s interest in movement and proportion. Saint Anne with the Virgin and Child (1515) was a preparatory drawing for a stained glass window, while Various Sounds (1515), a sheet of sketches depicting animals and creatures playing musical instruments, was probably prepared for a decorative project ordered by Emperor Maximilian.


text:
86x55mm stickers digitally printed
Short run stickers, ideal for promotions, packaging and product information. From 50 - 10,000 depending on size. Check out our other sticker options. Need more? Simply request a quote.
- stickers available in semi-gloss
- size 86x55mm or 90x55mm
- up to full colour one side or black and white


text:
Recently I finished reading Start with Why by Simon Sinek. The book was so fantastic and intriguing I even read the acknowledgements at the end, and trust me, I NEVER go that extra mile when reading books, especially non-fiction.
The author clearly points out that in order to succeed in our goals, visions and plans whether personally or career-wise we have to start with why. We have to know why we are inspired and empowered to do things the way we do them and once we know why we need to translate our vision to others.
If we never lose sight of why we are doing something, we never lose site of our passion and the reason we get out of bed every day. If we know why we stay motivated to go hard or go home and make a difference in others lives.
What is your reason why?


text:
Know more about this business than we do? Cool! Please submit any corrections or missing details you may have.Help us make it right
Lic 99627
Free Estimates On Installation & Repair
Walk-In Coolers & Freezers
Sale & Service
Lic 99627 Bonded
Heating & Air Conditioning
We Service All Brands
Commercial Refrigeration
Be the first OregonLive.com user to add photos or videos of All Systems Hvac Inc
Walk-In Coolers & Freezers, Sale & Service, Mobile Homes, Heating & Air Conditioning, Free Estimates On Installation & Repair, Commercial Refrigeration, We Service All Brands, Lic 99627 Bonded, Lic 99627, Bonded


text:
|Shop now!
Once I had the foam dots in place I adhered them all being careful to line things up and center them. The dots on top will keep the tab from going inside the package too far. It will keep the box lid in place on top of the package.
Here's what it looked like all put together but with the tab slid out to read the verse.
It slides in and out so you can personalize it.
Lastly I colored up the image to match the papers I chose. Aren't they adorable?! I'm a huge animal lover so I adore this new line. We don't have armadillos where I live so I was pretty fascinated by them when I saw them live in person in Florida. I hope you love them too!


text:
Genre: Fantasy, Drama
Year: 2011
Country: United States
Director: Terrence Malick
Runtime: 139 min
Actors: Brad Pitt, Sean Penn, Jessica Chastain, Tye Sheridan, Hunter McCracken, Laramie Eppler, Fiona Shaw
Jack comparable history with the history of any person on the planet. The protagonist plunges into the depths of adventure as a child, and now, from the perspective of an adult, trying to analyze the way that he went over the many years. Perhaps in the past, Jack made a lot of mistakes, but each of them became an important point in the development of his personality seychas.Kogda protagonist only grew, he had three brothers, and his mother was trying to bring them up in the Christian tradition. However, his father insisted that the children have to fight for their own happy future, be able to resist the existing order in society. As a result, different approaches to the education of the parents often put Jack in the present deadlock. However, he was ready for such problemam.Bol losses and defeats the man began to realize in those days, when I first learned about true love. That's just the fate of Jack - this is not a sprint but rather a marathon lasting from around the tragic, joyful and amazing events. What did Jack will do in your life, and what the outcome of his way? This viewer learns only in the final of this amazing and rich history. With TK-Movie.com you can download The Tree of Life free movie in HDrip.


text:
From the makers of
Track & Manage All Of Your Investments
Try It Now!
Sign Up
Green Issues
All Concepts
How To Invest
Personal Finance
Options 101
Sanofi-Aventis SA (SNY)
Topic Listing for Sanofi-Aventis SA
A-3 Other
Abstract 3069
Abstract 3069 Activity Mva 5t4 Alone Combination Either
Abstract 4007
Abstract 4067
Abstract 4514
Abstract 4514 Randomized Phase Study S-1 Alone Versus
Abstract 537 Estrogen Receptor Expression Efficacy Docetaxel Early
Abstract 5508
Abstract 5508 Vegf-trap Patients Pts Recurrent Platinum-resistant Epithelial
Abstract 7627 Phase Study Efficacy Safety Intravenous Ave0005
Abstract 9526 Child Matters Program Uicc-sanofi-aventis Partnership Improve
Abstract Lba1008
Abstract Lba5
Abstract Lba5 Final Results Eortc Intergroup Randomized Phase
Acambis Plc
Accounting Financial Statement Preparation Procedures
Accounting Transactions Foreign Currencies Individual Accounts
Accounts Committee
Accounts Receivable
Accumulated Other Comprehensive Income
Acomplia Recommended Approval European Union
Acomplia Rimonabant
Acomplia Rimonabant Receives Marketing Authorisation European Union
Acquired In-process
Acquired In-process Research Development
Acquisition Advances Emerging Markets Strategy
Action 2005 Employee Share Ownership Plan
Action Been Undertaken Make Offer Public Notes Described
Active Trial
Active-a Active-i Program Continue
Activity Indication Further Justifies Ongoing Phase Study Trist
Activity Mva 5t4 Alone Combination Either Interleukin-2 Interferon-alpha
Actonel Optinate Acrel
Actonel Patent Litigation
Acts-gc Study
Acute Coronary Syndrome
Acute Coronary Syndrome Acs
Acute Coronary Syndrome Undergoing Intervention
Acute Hepatic Failure Severe Liver Injury Some Cases
Adacel Vaccine Development
Additional Disclosures Groups French Gaap Financial Statements
Additional Disclosures Groups Gaap Financial Statements
Additional Information
Address Principal Executive Offices
Adjusted Consolidated Income Statement
Adjusted Consolidated Net Income
Adjusted Earning Per Share
Adjusted Earnings Per Share
Adjusted Eps 528 128162 128106 2005 198 Excluding
Adjusted Eps Excluding Selected 110
Adjusted Eps Growth 150 Excluding Selected
Adjusted Income Statement Excluding Selected
Adjusted Net Income
Adjusted Pro Forma Net Income
Adjusted Pro Forma Results
Adjusted Proforma Basis
Adjustments Consolidated Financial Statements Reflect Application Purchase Accounting
Adjuvant Colon Cancer Setting
Adult Adolescent Boosters
Adults Children Age Older
Advanced Colorectal Cancer Setting
Advanced Non Small Cell Lung Cancer
Aflibercept Vegf Trap
Aflibercept Vegf Trap Oncology
Aflibercept Vegf-trap
After Change Method Accounting Employee Benefits
After Consultation Stock Market Authorities France United States
After End Shareholders Annual General Meeting
After Surgery Patients Resectable Liver Metastases Colorectal Cancer
Against Leading Cause Death Developing Countries
Agreal Product Litigation
Agreement Procter Gamble Pharmaceuticals
Agreement Settle Plavix Litigation Apotex
Albemarle Arbitration
Albemarle Litigation
Allegra Line Products
Allegra Litigation
Allegra Patent Litigation
Allegra Telfast
Allegra-d Fexofenadine Hcl 180 Pseudoephedrine 240 Extended Release
Allergic Conditions
Allergic Rhinitis
Allergies Rise Longer-lasting Allergy Seasons Patients Desire Fast
Alliance Agreements Bristol-myers Squibb Bms
Alliance Agreements Organon
Alliance Agreements Pfizer
Alliance Agreements Procter Gamble Pharmaceuticals
Alliance Arrangements Bristol-myers Squibb Bms
Allocation Profits
Allocation Shares Purchased Prior 2004 Further Re-allocations
Alopexx Pharmaceuticals Llc
Alopexxs Novel Human Antibody
Alvocidib Refractory Chronic Lymphocytic Leukemia Cll
Amaryl Amarel Solosa
Ambien Improved Sleep Quality Impact Daily Activities Mdd
Ambien Patent Litigation
Ambien Zolpidem Tartrate Extended-release Tablets
Ambien Zolpidem Tartrate Product Litigation
Ambitious Drug-monitoring Program Started Africa
Amendments Affecting Class Shareholders Rights
Amortization Impairment Intangibles
Amortization Intangibles
Amortization Other Intangible Assets
Amyris Biotechnologies
Animal Health
Animal Health Merial
Announcement 2005 Transfer Sanofi-aventis 100 Plavix Rights Japan
Annual General Meeting
Annual Meeting
Annual Ordinary Meetings
Annual Payments Participating Share Series Pssa
Annual Payments Pssas
Antithrombotic Therapy
Antoine Ortoli
Apidra Insulin Glulisine
Apidra Insulin Glulisine Rdna Origin
Apidra Solostar
Apollo Study Findings
Apotex Settlement Claim
Appendix 2005 Adjusted Consolidated Statement Income
Appendix 2005 First-half Adjusted Consolidated Financial Statements
Appendix 2005 First-half Consolidated Income Statement
Appendix 2005 First-half Net Sales Product
Appendix 2005 Full-year Adjusted Consolidated Financial Statements
Appendix 2005 Full-year Net Sales Product
Appendix 2005 Full-year Reconciliations Consolidated Income Statement Adjusted
Appendix 2005 Net Sales Product
Appendix 2005 Reconciliation Consolidated Statement Income Adjusted
Appendix 2009 9-month Net Sales Animal Health Product
Appendix Adjusted Consolidated Income Statements 2005
Appendix Consolidated Net Sales Business Segment
Appendix Definitions Non-gaap Financial Indicators
Appendix Explanatory Notes
Appendix Explanatory Notes Financial Indicators
Appendix Reconciliation Consolidated Income Statement Adjusted 2005
Appendix Reconciliation Proforma Statement Income Adjusted 2003 2004
Appendix Sanofi-aventis Simplified Consolidated Balance Sheets Statement Cash
Appendix Simplified Consolidated Balance Sheet
Appendix Simplified Consolidated Cash Flow Statement
Appendix Simplified Consolidated Statement Cash Flows Balance Sheet
Appendix Trend Selected Adjusted Net Income
Appendix Trend Selected After Tax Adjusted Net Income
Appendix Trends Selected Adjusted Income Statement After Tax
Appendix Trends Selected Adjusted Income Statement Net Tax
Application Change Control Clauses
Applications European Union
Appointments Governance Committee
Approval Based Clinical Trial Tax 324
Approval Based Pediatric Clinical Trial
Approval Dividends
Approval European Union
Approved Europe
Approved European Union
Aprovel Avapro Karvea
Arava Antitrust Litigation
Arch Fam Med
Armour Blood Products Litigation
Asaq Field-monitoring Program
Asco Meeting
Assessment Objectives End 2006
Assets Held Sale
Assets Held Sale Liabilities Related
Assets Liabilities Business Segment
Assets Liabilities Segment
Assumes Exchange Rate 125 Euro Sensitivity Fluctuations Estimated
Assumption Sanofi-aventis Obligations Aventis
Athena Study
Atrial Fibrillation
Atrial Fibrillation Flutter
Atrial Fibrillation Flutter Stroke
Atrial Fibrillation Most Frequent Cardiac Arrhythmia Affects Adults
Atrial Fibrillation Patients
Attendance Person
Attendance Shareholders Meetings Proxies Votes Mail
Audit Committee
Audit Committee Financial Expert
Audit Committee Pre-approval Procedures
Audit Committeee
Available Japan 2008
Aventis Animal Nutrition
Aventis Behring
Aventis Cropscience
Aventis Inc Hoechst Gmbh Share Purchase Option Plans
Aventis Inc Hoechst Share Purchase Option Plans
Aventis Pharma Limited India
Awards Shares
Awareness Treatment Control
B10 Cash Equivalents
B10 Trade Receivables
B10 Treasury Shares
B101 Provisions Pensions Other Long-term Benefits
B102 Currency Derivatives Used Manage Financial Risk Exposures
B11 Net Deferred Tax Position
B11 Provisions Risks
B11 Publication Clinical Trial Results
B11 Short-term Investments Deposits
B11 Treasury Shares
B12 Filings Marketing Approval European Japanese Authorities New
B12 Net Deferred Tax Position
B12 Provisions Risks
B12 Revenues
B122 Competing Bid Share Capital Zentiva
B13 Cost Sales
B13 Defense Products
B13 Emission Rights
B13 Legal Arbitral Proceedings
B13 Principal Commercial Commitments Collaboration Agreements
B13 Revenue Recognition
B14 Cost Goods Sold
B14 Divestments Acquisitions Alliances
B14 Financial Income Expenses
B14 Legal Arbitral Proceedings
B14 Research Development Expenses
B14 Revenue Recognition
B15 Cost Sales
B15 Income Tax Expense
B15 Other Current Operating Income
B15 Research Development
B151 Financial Expenses
B152 Financial Income
B16 Income Tax Expenses
B16 Other Current Operating Expenses
B16 Other Operating Income Expense Net
B16 Research Development Expenses
B16 Segment Information
B17 Amortization Intangibles
B17 Operating Profit
B17 Other Current Operating Income
B17 Other Operating Income
B17 Segment Information
B18 Amortization Impairment Intangibles
B18 Other Current Operating Expenses
B18 Other Operating Expenses
B18 Restructuring Costs
B19 Amortization Intangibles
B19 Financial Income Expense Net
B19 Impairment Property Plant Equipment Intangibles
B20 Exceptional
B20 Operating Income Before Restructuring Impairment Property Plant
B20 Other Operating Income Expenses
B20 Restructuring Costs
B21 Impairment Property Plant Equipment Intangibles
B21 Income Taxes
B211 Financial Expenses
B212 Financial Income
B22 Employee Benefits
B22 Income Tax Expense
B22 Other Operating Income Expenses
B23 Employee Benefit Obligations
B23 Financial Instruments
B231 Financial Expenses
B232 Financial Income
B24 Earnings Per Share
B24 Income Taxes
B24 Share-based Payment
B241 Stock Option Plans
B242 Employee Share Ownership Plans
B242 Employee Stock Ownership Plans
B25 Earnings Per Share
B25 Employee Benefit Obligations
B26 Segment Information
B26 Segment Reporting
B261 Stock Option Plans
B262 Employee Stock Ownership Plans
B27 Earnings Per Share
B27 Management Capital
B27 New Iasb Standards Interpretations Applicable 2007 Onwards
B28 New Iasb Standards Amendments Interpretations Applicable 2009
B28 New Iasb Standards Interpretations Applicable 2008 Onwards
B28 Segment Reporting
B29 New Iasb Standards Interpretations Applicable 2006 Onwards
B31 Accounting Treatment
B32 Goodwill
B41 Pharmaceutical Research Development
B41 Research Development Not Acquired Business Combination
B42 Other Intangible Assets
B43 Intangible Assets Acquired Business Combination
B61 Impairment Property Plant Equipment Goodwill Intangible Assets
B61 Impairment Property Plant Equipment Intangible Assets
B62 Impairment Investments Associates
B63 Reversals Impairment Losses Charged Against Property Plant
B71 Financial Assets
B71 Share Capital
B72 Derivative Instruments
B73 Impairment Financial Assets
B73 Repurchase Sanofi-aventis Shares
B74 Hedging
B74 Stock Option Plans
B75 Financial Liabilities
B75 Number Shares Used Compute Diluted Earnings Per
B76 Fair Value Financial Instruments
B77 Derecognition Financial Instruments
B81 Financial Assets
B81 Share Capital
B82 Impairment Financial Assets
B82 Market Value Debt
B82 Market Value Debt Net Cash Equivalents
B82 Repurchase Sanofi-aventis Shares
B83 Derivative Instruments
B83 Stock Option Plans
B84 Hedging
B84 Number Shares Used Compute Diluted Earnings Per
B85 Financial Liabilities
B86 Fair Value Financial Instruments
B87 Derecognition Financial Instruments
B88 Risks Relating Financial Instruments
B92 Currency Derivatives Used Manage Financial Risk Exposures
B92 Market Value Debt
Background Pertussis
Barcelona 2006
Barring Major Adverse Events Sanofi-aventis Expects Full-year Adjusted
Based Good First-half Results Barring Major Adverse Events
Basis Consolidation
Basis Preparation
Basis Preparation Financial Information Accounting Policies
Basis Preparation Financial Statements Accounting Policies
Basis Preparation Interim Consolidated Financial Statements
Bcirg 006 Study
Before Appropriation Profit
Beijing Economic Technological Development Area
Believe Developed Sales Useful Measurement Tool Because They
Believe Pro Forma Combined Developed Sales Useful Measurement
Belén Garijo
Bethesda 2007
Better Answer Global Health Needs
Biologically Derived Ingredients Face Consumer Resistance Adversely Affect
Biologically Derived Ingredients Face Patient Resistance Adversely Affect
Biologically-derived Ingredients Face Consumer Resistance Adversely Affect Sales
Biometrics Center Beijing
Biotinylated Idraparinux
Bipar Sciences
Bite Antibodies
Bms Alliance
Board Directors
Board Directors 2008
Board Directors Borrowing Powers
Board Directors Committees
Board Practices
Boards Powers
Bonus Profit Sharing
Bordetella Pertussis
Brazilian Antitrust Claims
Breakdown Sites Between Owned Leased
Breakdown Sites Between Owned Leased Worldwide
Breakdown Sites Function France
Breakdown Sites Function France Worldwide
Breakdown Sites Function Worldwide
Breakdown Sites Nature
Breast Cancer
Brief Description Internal Control Procedures Associated Processes
Bring Greater Flexibility Patients Opportunity Earlier Initiation Insulin
Bristol-myers Squibb
Bristol-myers Squibb Bms
Bristol-myers Squibb Bms Alliance
Bristol-myers Squibb Global Pharmaceutical Related Health Care Products
Building Long History Allergy Treatment Arena Opportunity Allows
Bulletin Des Annonces Légales Obligatoires
Business Combination Between Sanofi-aventis Aventis
Business Combinations
Business Travel Authorization Expenses Report Procedure
C312 Net Sales Geographic Region
Cancer Facts Figures 2004
Cape Town South Africa 2006
Capital Expenditures Divestitures
Capital Leases
Cardiovascular Outcomes
Cardiovascular Thrombosis
Cardizem Antitrust Litigation
Case Questions Regarding Settlement Offer
Case Questions Regarding Tendering Shares
Cash Equivalents
Cash Flow
Cash Flow Presentation
Cassiopea Study
Cautionary Statement Regarding Forward-looking Statements
Cayman Islands Taxes
Central Group Functions Simplified Reactive Organization
Central Nervous System
Central Nervous System New Approaches Sleep Disorders Depression
Cet Webcast
Chairman Board Directors Report-internal Control
Chairman Chief Executive Officer
Chairman Vice-chairman Board Directors
Challenges Patented Products
Change Accounting Method
Change Consolidation Method Prior Period Recalculated Basis Used
Change Consolidation Percentage Consolidated Entity Prior Period Recalculated
Change Control Anti-takeover
Change Method Consolidation
Change Presentation
Change Proportionate Consolidation Method Equity
Changes Marketing Status Competitive Environment Major Products Adversely
Changes Previous Accounting Policies
Changes Share Capital 2005
Changes Share Capital 2006
Changes Share Capital 2007
Changes Share Capital 2008
Changes Share Capital Between 2005 2006
Changes Shareholders Rights
Chicago Tokyo Japan Paris France 2007-
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Chief Strategic Officer Cso
Child Matters
Children Nasal Symptoms Associated Perennial Allergic Rhinitis
Children Through Age
Chris Viehbacher
Christian Lajoux
Christopher Viehbacher
Chumakov Institute Poliomyelitis Viral Encephalitides
Cipro Antitrust Litigation
Cipro Litigation
Cirrhotic Ascites
Cisplatin 5-fluorouracil Tpf Regimen Increases Survival Approval Hope
Civil Suits Department Justice Relating Anzemet
Civil Suits Pricing Marketing Practices
Civil Suits-pricing Marketing Practices
Claims Investigations Relating Marketing Practices Competition Law Adversely
Claims Relating Marketing Practices Adversely Affect Business Results
Clariant Specialty Chemicals Business
Clariant-specialty Chemicals Business
Class Action Suits-pricing Marketing Practices
Clexane Lovenox
Clexane Lovenox Approved Japan
Clexane Lovenox Enoxaparin
Clin Infect Dis
Clinical Considerations Eloxatin
Clinical Oncology Annual Meeting
Clinical Studies
Clinical Trial
Clinical Trials Rimonabant
Clopidogrel Applications Germany
Clopidogrel Germany
Clostridium Tetani
Cobra Study
Code Ethics
Code Financial Ethics
Collaboration Enables Reach Goal Some Scientists Only Dream
Collaborations Parties Expose Risks They Assert Intellectual Property
Collaborations Parties Expose Risks They Claim Intellectual Property
Collaborative Agreements
Colorectal Cancer
Colorectal Cancer Leading Cause Death
Combined Cisplatin Demonstrates Significant Improvement Overall Survival Advanced
Comments Adjusted Proforma Statement Income
Comments Product
Comments Therapeutic Class
Commercial Commitments
Commercial Launch Planned Summer 2009
Commitments Favor Executive Directors Post 2008
Committed Global Polio Eradication Initiative
Common Stock 2004 Was
Comparable Net Sales
Comparable Sales
Comparable-basis Net Sales
Compared Adjusted 2005
Compensation Appointments Governance Committee
Compensation Committee
Compensation Options Shares Awarded Christopher Viehbacher
Compensation Options Shares Awarded Gérard Fur Chief Executive
Compensation Options Shares Awarded Jean-françois Dehecq
Compensation Payable Paid Christopher Viehbacher
Compensation Payable Paid Gérard Fur Chief Executive Officer
Compensation Payable Paid Jean-françois Dehecq
Compensation Pension Arrangements Corporate Officers
Compensation Pension Arrangements Gérard Fur
Compensation Pension Arrangements Jean-françois Dehecq
Compensation Senior Management
Components Internal Control
Composition Board Directors
Composition Board Directors 2007
Composition Operation
Compounds Currently Later-stage Development Thrombosis
Conference Call
Conference Call Held Tuesday 2005 400 Cet
Confined Intensive Care Unit
Confirmation 2008 Guidance
Conjugate Vaccine Technology
Consent Independent Registered Public Accounting Firm
Consolidated Balance Sheet
Consolidated Balance Sheet Debt
Consolidated Balance Sheets
Consolidated Balance Sheets Assets
Consolidated Balance Sheets Liabilities Equity
Consolidated Cash Flow
Consolidated Cash Flow Net Debt
Consolidated Cash Flow Statement Balance Sheet 2008 Refer
Consolidated Cash Flows Balance Sheet 2005
Consolidated Financial Information 2004 Includes Statements Aventis Subsidiaries
Consolidated Financial Statements
Consolidated Financial Statements Other Information
Consolidated Financial Statements Presented Appendix 3the Date
Consolidated Gross Profit
Consolidated Net Debt
Consolidated Net Financial Income Expense
Consolidated Net Income Loss
Consolidated Net Income Loss Attributable Equity Holders
Consolidated Net Sales
Consolidated Net Sales Sanofi-aventis
Consolidated Operating Loss
Consolidated Statement Cash Flow Balance Sheet 2007
Consolidated Statement Cash Flows
Consolidated Statement Cash Flows Balance Sheet
Consolidated Statement Cash Flows Balance Sheet 2006
Consolidated Statement Cash Flows Balance Sheet 2008
Consolidated Statements Cash Flows
Consolidated Statements Other Financial Information
Consolidated Statements Recognized Income Expense
Consumer Australia Now Completed
Contact Anne Bancillon
Contact Media Inquiries
Context Worldwide Financial Crisis Liquidity Constrained
Contingencies Arising Certain Business Divestitures
Contingent Csl Consideration
Contraindications Precautions
Contribution Equity Investees
Controlling Mealtime Blood Sugar Spikes Crucial Part Managing
Controls Procedures
Conversion Aventis Stock Options
Conveyance Transfer Shares
Coronary Artery Disease Acute Syndrome
Coronary Artery Disease Cad Acute Syndrome Acs
Corporate Governance
Corporate Purposes
Corynebacterium Diphtheriae
Counterfeit Products Harm Business
Counterfeit Products Harm Business Sanofi-aventis
Counterparty Risk
Crc Rule 2000-06
Crc Rule 2002-10
Credit Facilities
Critical Accounting Reporting Policies
Critical Limb Ischemia Severe Costly Condition Following Episode
Cumulative Preference Shares Series
Currency Forward Options Contracts
Current-oasis Trial
D10 Accounts Receivable
D10 Other Current Assets
D10 Short-term Investments Deposits
D11 Deferred Income Taxes
D11 Financial Assets Current
D11 General Description
D11 Net Sales
D11 Other Current Assets
D110 Impairment Property Plant Equipment Intangibles
D111 Gains Losses Disposal Litigation
D111 Net Sales Business Segment
D112 Net Sales Geographic Region
D112 Operating Income
D113 Financial Income Expenses
D113 Worldwide Presence Plavix Aprovel
D114 Income Before Tax Associates
D115 Income Tax Expense
D116 Share Profit Loss Associates
D117 Net Income
D118 Net Income Attributable Minority Interests
D119 Net Income Attributable Equity Holders
D12 Cash Equivalents
D12 Financial Assets Current
D12 Other Revenues
D121 Share Capital
D122 Change Accounting Method
D123 Adjustments Shareholders Equity Related Merger Between Sanofi
D124 Impact Acquisition Aventis Shareholders Equity
D126 Repurchase Sanofi-aventis Formerly Sanofi-synthélabo Shares
D13 Cash Equivalents
D13 Gross Profit
D13 Minority Interests
D13 Pro Forma Financial Information
D13 Pro Forma Information
D131 Share Capital
D132 Adjustments Shareholders Equity Related Sanofi Synthélabo Merger
D133 Repurchase Sanofi-aventis Shares
D134 Reduction Share Capital
D135 Cumulative Translation Differences
D136 Recognized Directly Shareholders Equity
D14 Debt
D14 Research Development Expenses
D15 Selling General Expenses
D151 Provisions Pensions Other Benefits
D151 Share Capital
D152 Capital Increase Reserved Employees Employee Share Ownership
D152 Restructuring Provisions
D153 Adjustment Shareholders Equity Related Sanofi Synthélabo Merger
D153 Capital Increase Reserved Employees Employee Share Ownership
D153 Other Provisions
D154 Other Long-term Liabilities
D154 Other Non-current Liabilities
D154 Repurchase Sanofi-aventis Shares
D155 Reduction Share Capital
D156 Cumulative Translation Differences
D157 Other Recognized Directly Equity
D157 Recognized Directly Equity
D159 Number Shares Used Compute Diluted Earnings Per
D16 Minority Interests
D16 Other Current Liabilities
D16 Other Operating Income Expenses
D17 Amortization Intangibles
D17 Debt Cash Equivalents
D17 Short-term Debt
D18 Derivative Financial Instruments
D18 Personnel Costs
D182 Restructuring Provisions
D183 Other Provisions
D184 Other Non-current Liabilities
D19 Other Current Liabilities
D19 Other Current Operating Income
D19 Restructuring Costs
D20 Derivative Financial Instruments Market Risks
D20 Other Current Operating Expenses
D202 Commitment Buy Out Shares Subsidiaries
D202 Equity Derivatives
D203 Other Commercial Commitments
D21 Personnel Costs
D21 Restructuring Costs
D22 Adjusted Net Income
D22 Legal Arbitral Proceedings
D22 Other Operating Income Expense Net
D22 Other Operating Income Expenses
D23 Adjusted Earnings Per Share Eps
D23 Financial Income Expense Net
D231 Financial Income
D232 Financial Expenses
D24 Exceptional
D24 Income Tax Expense
D24 Personnel Costs
D25 Other Current Operating Income
D25 Other Operating Income
D251 Business Segments
D26 Minority Interests
D26 Other Current Operating Expenses
D26 Other Operating Expenses
D261 Repurchase Hoechst Minority Shareholders
D262 Acquisition Commercial Rights Plavix Japan
D263 Disposal Interest Wacker-chemie Gmbh
D27 Related Party Transactions
D27 Restructuring Costs
D28 Gains Losses Disposals Litigation
D28 Other Operating Income Expenses
D28 Split Net Sales
D29 Financial Income Expenses
D29 Segment Information
D291 Financial Expenses
D292 Financial Income
D30 Income Tax Expense
D31 Share Profit Loss Associates
D32 Minority Interests
D32 Net Income Attributable Minority Interests
D33 Related Party Transactions
D34 Split Net Sales
D351 Business Segments
D352 Information Geographical Segment
Daiichi Pharmaceutical
Daptacel Vaccine
Data Answer World Health Organization Calls Demonstration Cross-reactivity
Data Easd Suggests Better Glycaemic Control Possible Using
Data Exclusivity Protection
Data Presented Asco 2007 Highlights Sanofi-aventis Commitment Oncology
David Williams
Ddavp Antitrust Litigation
Ddavp Litigation
Ddavp Patent Litigation
Debt Cash Equivalents
Debt Net Cash Equivalents Currency Value Redemption
Decreases Share Capital
Deep Vein Thrombosis Pulmonary Embolism
Defense Lovenox Patent United States
Defense Plavix Patent United States
Defense Plavix Patent United States Europe
Defense Products
Deferred Income Tax Above Adjustments
Deferred Income Tax Effect Above Adjustments
Deferred Tax Equity Investees
Deferred Tax Intercompany Margins
Deferred Tax Liability Acquired In-process Research Development
Deferred Tax Related Acquired Stock Options
Deferred Taxes
Deferred Taxes Equity Investees
Definition Objectives Internal Control
Delays Onset Reduces Occurrence Repeat Heart Attacks Window
Deliberations Board
Demonstration Good Cardiovascular Tolerability Alfuzosin
Dengue Fever
Depend Parties Manufacture Supply Substantial Portion Raw Materials
Depend Parties Manufacturing Active Ingredients Some Products Substantial
Depend Parties Marketing Some Products Act Ways Harm
Depend United States Market Significant Part Current Future
Derivative Financial Instruments
Derivative Instruments
Detail Material Impacts 2004 Proforma Statement Income Arising
Developed Sales
Developed Sales Aprovel Avapro Karvea
Developed Sales Plavix Iscover
Developing Worldwide Market Presence Controlling Operating Results
Development Programs Stopped Since 2005
Development Stage
Developments Relating Defense Sanofi-aventis Products
Developments Relating Expansion Presence Japan
Developments Relating Filings Marketing Approval European Healthcare Authorities
Diabetes Care
Diabetes Mellitus
Differences Presentation Between French Gaap
Differences Resulting Application Ifrs
Difficult Environment Another Growth Adjusted Eps Excluding Selected
Directors Age Limits
Directors Compensation
Directors Senior Management
Directors Share Ownership Requirements
Disclosure Controls Procedures
Discontinuation Commercialization Copaxone Sanofi-aventis North America Effective 2008
Discounting Long-term Provisions
Discovery Research
Discovery Research Operations
Discovery Stage
Disease Endemic United States
Distribution Dividends
Distribution Formula
Diversified Global Leader Healthcare
Divestment Exubera Rights Interest Diabel
Divestment Notre Dame Bondeville Site
Divestments Acquisitions Alliances
Dividend 151 Increase 128175 Per Share Submitted Approval
Dividend Increase 151 128175 Per Share Paid
Dividends Ordinary Shares
Division Anesthesia Analgesia Rheumathology Products
Division Cardiovascular Renal Products
Docetaxel Injection Concentrate
Documents Display
Donna Vitter
Dronedarone Multaq
Dronedarone Press Office Http Wwwdronedarone-atrial-fibrillation-pressofficecom References
Earnings Per Share
Earnings Per Share Attributable Sanofi-aventis Shareholders
Earnings Per Share Eps
Edmonton Canada Paris France 15th 2005
Effect Changes Scope Consolidation
Eligard Patent Litigation
Eloxatin -based Therapy Central Research Targeted Agents Metastatic
Eloxatin Europe
Eloxatin Oxaliplatin Patent Litigation
Eloxatin Patent Litigation
Eloxatine European Patent Litigation
Eloxatine Patent Litigation
Employee Benefits
Employee Savings Schemes
Employee Savings Schemes Collective Retirement Plan
Employee Share Ownership
Employee Stock Options
Employees Function
Employees Geographic Area
Employees Main Category Function
Encouraged Results Seeing Aflibercept Vegf Trap Especially Evidence
Encouraging Data Show Potential Pre-pandemic Vaccine Offer Broad
Encouraging Results Vegf Trap Aflibercept Highlighted Asco 2007
End 2007
Enforceability Civil Liabilities
Engl Med
Environmental Liabilities Compliance Costs Significant Adverse Effect Operating
Environmental Liabilities Compliance Costs Significant Adverse Effect Results
Eortc 24971 Tax 323 Study
Eortc 24971 Tax 323 Study Identify Neoadjuvant Chemotherapy
Eplivanserin Ciltyri
Eplivanserin Sleep Maintenance Insomnia
Epoc Study
Epoc Study Ambitious Trial Largest Clinical Kind Conducted
Equity Derivative Instruments
Equity-accounted Companies
Estate Gift Taxes Transfer
Ethical Charter Purchasing
Eur Heart
Eur Respir
Euridis Adonis
Eurolist Market
Euronext Paris Market
Europe North America
European Commissions Pharmaceutical Sector Inquiry Lead Significant Legislative
European Expands Indication Plavix Clopidogrel Bisulfate Offering New
European Fines
European Imposes Fine Certain Mcaa Producers
Evaluation Board Procedures
Event Subsequent Balance Sheet Date 2007
Events Subsequent Balance Sheet Date 2008
Events Subsequent Balance Sheet Date 2009
Except Patients Suffering Ongoing Major Depression
Exchange Controls
Exchange Non-monetary Assets
Exchange Rate Information
Exchange Rates
Excluding Net Sales Allegra Amaryl United States
Excluding Selected
Excluding Selected 2005 2006 Include 128384 Post-tax Gain
Excluding Selected 2005 2006 See Appendix Eps Risen
Excluding Selected Adjusted Net Income Was 1281797 145
Excluding Selected Adjusted Net Income Was 1283504 173
Exclusive Collaboration Discovery Pi3k Inhibitors
Executive Committee
Executive Committee Management
Executive Vice President Pharmaceutical Operations
Exemptions Exceptions Ifrs
Existing Option Plans 2006
Existing Option Plans 2007
Existing Option Plans 2008
Expand Strategic Antibody Collaboration
Expenditure Commitment Authorization Procedure
Expert Audits
Expert Opinion Drug Delivery
Extension Indication Sought Pediatric Population United States Project
Exubera Alliance
F33 Pensions Postretirement Benefits
F34 Earnings Per Share
F35 Accumulated Other Comprehensive Income
F36 Recent Accounting Pronouncements
Face Uncertainties Over Pricing Pharmaceutical Products
Face Uncertainties Over Pricing Reimbursement Pharmaceutical Products
Facility Shanghai
Fact Blood Sugar Levels Reduced Along Weight Loss
Fail Adequately Renew Product Portfolio Whether Through Own
Fair Value
Fair Value Long-term Debt
Fda Approval Significant Milestone Evaluation Treatment Options Patients
Fda Approves Lovenox Enoxaparin Sodium Injection Most Severe
Fifth Consecutive Dose
Fight Fatal Disease
Finalization Preliminary Purchase Price Allocation
Finance Leases
Financial Accounting Standards Board Fasb Recently Issued Following
Financial Assets
Financial Assets Non-current
Financial Calendar
Financial Code Ethics
Financial Commitment Related Offer Zentiva Shares
Financial Foreign Exchange Derivatives 2005
Financial Foreign Exchange Derivatives 2006
Financial Foreign Exchange Derivatives 2007
Financial Foreign Exchange Derivatives 2008
Financial Foreign Exchange Risk
Financial Income Expenses
Financial Information
Financial Instruments
Financial Investment Authorization Procedure
Financial Liabilities
Financial Presentation Alliances
Financial Statements Other Communications Shareholders
Financial Statements Presented Accordance Ias
Financial Timetable
Financing Aventis Acquisition
Financing Aventis Acquisition 2004 Refinancing Debt 2005
Financing Controlling
Financing Treasury Procedures
First-half Business Net Income
First-half Consolidated Financial Statements Been Subject Limited Review
First-half Net Sales
First-half Net Sales Product
Fluctuations Currency Exchange Rates Adversely Affect Results Operations
Fluzone Vaccine
Focus Biologics
Following Market Share Ranking Information Based Sales Data
Foreign Currency Translation
Foreign Currency Translation Financial Statements Subsidiaries
Foreign Exchange Fluctuations Adversely Affect Dollar Value Adss
Form Shares
Forward Looking Statement
Forward Looking Statements
Forward Looking Statements Merck
Forward Looking Statements Regeneron
Forward Looking Statements Regeneron Pharmaceuticals Inc
Forward Looking Statements Sanofi-aventis
Forward Looking Statements Schering-plough
Forward-looking Statements
Forward-looking Statements -sanofi-aventis
Forward-looking Statements Regeneron
Forward-looking Statements Sanofi-aventis
Fov 1101 Prednisporin
Fov 2302
Fov 2304
Fovea Pharmaceuticals
France Heart Sanofi Pasteur Industrial Operations
Free Translation French Language Original
French Descriptive Report Internal Controls
French Gaap
French President Nicolas Sarkozy State Visit China
French President Nicolas Sarkozys State Visit
French Taxes
Full-year Adjusted Eps Growth Least
Full-year Demonstrated Ability Deliver Eps Growth Penalized Generics
Full-year Guidance
Full-year Net Sales
Full-year Net Sales Product
Further Development Other Types Cancer
Further List Description Risks Uncertainties Found Pfizers Annual
Further Positive Phase Results Eplivanserin
Future Events
Future Joint Venture Global Leader Animal Health
Ga-epo Patent Litigation
Gaap Reconciliation
Gaap Reconciliation Presentation Differences
Gains Losses Disposal Litigation
Gains Losses Disposals Litigation
Gastric Cancer
Gastric Stomach Cancer
Gender Discrimination
General Informations
General Meeting Shareholders
General Policy
General Shareholders Meetings
Generic Versions Some Products Approved Sale Major Markets
Geographical Split 2009 First-half Net Sales Vaccines Segment
Gilles Brisson
Gilles Lhernould
Global Focused Organizations Discovery Development
Global Media Contact
Global Media Relations
Glossary Patent Terminology
Glycemic Control Between Patients Using Lantus Versus Detemir
Gmt Conference Call Webcast
Good 2009 Performance
Good Performance 2009
Good Sales Growth Despite Introduction Generics Products
Goodwill Amortization
Government Investigations Competition Law Regulatory Claims
Government Investigations Plavix Settlement
Government Investigations Pricing Marketing Practices
Government Investigations-pricing Marketing Practices
Government Readiness Program
Gregory Irace
Gross Profit
Group Internal Audit
Groups Commitments
Growing Threat
Growth Net Sales Expressed Constant Structure Basis Exchange
Guarantees Given
Guarantees Received
Guidance 2006 Raised Basis First-half Results
Guidance Raised
Guidance Raised Based Good Results Achieved 2007 Full-year
Guidance Reiterated
Gérard Fur
Haemophilus Influenza
Haemophilus Influenzae
Half 2005
Half 2006
Half 2007
Half 2008
Half-year Management Report
Hangzhou Binjiang New Development Zone
Hanspeter Spek
Head Neck Cancer
Head Neck Cancer Deadly Disease
Health Outcomes Treatment Satisfaction Patients Using Lantus Versus
Health Safety Environment
Health Safety Environment Hse
Healthcare Costs Patients Using Lantus Therapy
Heart Disease Stroke Statistics 2006 Update
Heinz-werner Meier
Help Patients Diabetes Improve Glycemic Control
Hib Disease
Highlighted World Congress Cardiology
Highlights Half 2005 Pharmaceuticals Business
Highlights Half 2005 Vaccines Business
Highlights Improved Offer
History Development
Hoechst Gmbh Share Purchase Option Plans
Hoechst Shareholder Litigation
Hold Adss Rather Shares Difficult Exercise Some Rights
Holding Shares
Hospital-acquired Resistant Infections
Http Eceuropaeu Internal Market Accounting Ias Enhtm
Http Wwwcopaxonecom Indexhtml
Hub Global Health
Human Concludes Changes Prescribing Advice Necessary
Human Vaccines
Human Vaccines Activity
Ifrs Exemptions Exceptions
Ifrs Project
Immunization Recommendations
Impact Exchange Rates
Impact Ifrs
Impairment Intangible Assets
Impairment Investments
Impairment Property Plant Equipment Intangibles
Implementation Improved Offer
Implementation New Model
Implementation Offer
Important Information
Important Partnerships
Important Risk Information
Important Safety Information
Improved Blood Sugar Control Plus Weight Loss Achieved
Improved Offer
Improved Offer Zentiva Unanimous Backing Zentivas Board Directors
Ims Consolidated Net Sales Presented
Ims Data Related Sanofi-aventis Not Include Vaccines
In-process Research Development Acquired Part Business Combination
Income Before Tax Associates
Income Equity Investees Net
Income Presented Appendix
Income Statements 2004 Respectively Adjusted Net 2005 Was
Income Tax Expense
Income Tax Expenses
Income Taxes
Inconclusive Conflicting Data
Increase 2007 Full-year Earnings Growth Guidance
Increase 2008 Guidance
Increase 2008 Guidance See Page
Increase 2009 Guidance
Increase Breaks Down Following Components 128
Increases Share Capital
Incurred Substantial Debt Connection Acquisition Aventis Limits Business
Independent Registered Public Accounting Firms
Index Financial Statements
Indicate Check Basis Accounting Registrant Used Prepare Financial
Individual Shareholders
Induces Robust Seroprotective Antibody Response Children Adults
Industrial Relations
Industrial Sites
Industrial Sites Pharmaceutical Activity
Infect Dis Med Microbiol
Influenza H1n1 2009 Monovalent Vaccine
Influenza Immunization
Influenza Overview
Influenza Vaccine Production Sanofi Pasteur
Influenza Vaccines
Information Enquiries Please Contact
Information Legal Arbitration Proceedings
Information Relating Sanofi-aventis Combined General Meeting 2007
Information Reporting Backup Withholding
Information Reporting Backup Withholding Tax
Information Systems Usage Charter
Informations Please Visit
Infraserv Höchst
Ingrid Goerg-armbrecht
Initial Order Bulk Vaccine Valued 190
Institute Oneworld Health
Institutional Investors Analysts
Insulin Glargine Rdna Origin
Insulin Glulisine Rdna Origin
Insulin Glulisine Rdna Origin Injection
Insulin Lispro Part Basal-bolus Regimen
Insulin Therapy People Type Diabetes Generally Initiated Very
Insurance Risk Coverage
Intangible Assets
Integration Committees
Integration New Groups Activities Presents Significant Challenges Result
Interest Rate Forward Options Contracts
Interest Rate Risk
Interest Vegf-trap Driven Unique Characteristics High Potential Most
Interim Analysis Novel Regimen Taxotere Without Anthracyclines Appears
Interim Analysis Phase Study Shows Taxotere -based Regimens
Interim Results Following Initial Dose Vaccine
Internal Audit Charter
Internal Control Documentation Assessment Program Processes Contributing Preparation
Internal Control Documentation Evaluation Program
Internal Medicine
International Development
International Financial Reporting Standards Adoption
International Financial Reporting Standards Ifrs
Intra-dermal Route Vaccination
Introduction Key Figures Half 2006
Inventory Costs
Invest Substantial Sums Research Development Order Remain Competitive
Investments Advances Equity Investees
Investments Advances Non-consolidated Companies
Investments Associates
Ionamin Fen Phen Litigation
Irrevocable Purchase Commitments
Irrevocable Purchase Obligations
Japanese Phase Clinical Trial
Jean-claude Armbruster
Jean-claude Leroy
Jean-françois Dehecq
Jean-marc Podvin
Jean-michel Lévy
Jean-philippe Santoni
Jean-pierre Kerjouan
Karen Linehan
Karen Linehan General Counsel 174 Avenue France 75013
Ketek Cause Visual Disturbances Particularly Slowing Ability Accommodate
Key Figures Half 2007
Key Figures Half 2008
Key Milestone Preparing Pandemic Response Fall
Key Research Areas
Kroger Antitrust Claim
Laboratorios Kendrick
Lantus Insulin Glargine Rdna Origin
Lantus Insulin Glargine Rdna Origin Injection
Lantus Regimen Was Associated Reduced Risk Hypoglycemia Fewer
Lantus Solostar
Large Majority
Largest Shareholders Own Significant Percentage Share Capital Voting
Latin America Asia
Laurence Debroux
Legal Reserve
Legend Pharmaceutical Manufacturing Chemical
Liability Further Capital Calls
License Agreements
License Development Agreements
License Income Government Levies
Licensure Nations Vaccine Significant Milestone Pandemic Preparedness
Light Fully Human Monoclonal Antibody
Light Molecule
Limits Placed Board Powers Chief Executive Officer
Liquidation Rights
Liquidity Capital Resources
Liquidity Risk
List Appendices
Lock-up Period Shares Obtained Exercise Stock Options Chairman
Lock-up Period Shares Obtained Exercise Stock Options Disposition
Long-term Debt
Long-term Receivables Other Deferred Charges
Looking Forward Developing Collaboration Oxford Biomedica
Lovenox Antitrust Litigation
Lovenox Clexane
Lovenox Clexane Europe
Lovenox Patent Infringement Suit Decided Against Sanofi -aventis
Lovenox Patent Litigation
Lovenox Patent Trial Update
Lovenox Reissue Generic Filing
Lovenox Safety Syringe
Lung Cancer
Lung Cancer Study
Lyon France 2005
Lyon France 2006
Lyon France Swiftwater Usa 2005
Main Areas
Main Developments Portfolio
Main Events
Main Events Half Vaccines Business Related H5n1 Pandemic
Main Financing Debt Reduction Transactions Period
Main Included Financial Assets Non-current
Main Vaccines Products
Major Products
Malaria Patients Each
Management Committee
Management Control Procedures
Management Type Diabetes Not Only Focus Controlling Blood
Managerial Committees
Managing Human Resources
Managing Information Systems
Managing Legal Affairs
Mandatory Offers Subsequent Acquisition
Mandatory Offers Subsequent Acquisition Aventis
Manufacture Products Technically Complex Supply Interruptions Caused Unforeseen
Manufacture Products Technically Complex Supply Interruptions Product Recalls
Manufacturing Base Hangzhou
Marc Cluzel
Marie-hélène Laimay
Market Value Debt
Market Value Debt Net Cash Equivalents
Marketable Investment Securities
Marketing Distribution
Material Contracts
Material Impacts Application Fair Value Acquisition Accounting Combination
Material Impacts Application Purchase Accounting Acquisition Follows
Material Impacts Application Purchase Accounting Aventis Acquisition Restructuring
Material Impacts Arising Fair Value Acquisition Accounting Follows
Mcaa Industry Litigation Investigation
Measurement Date Securities Issued
Measurement Impairment Loss Intangible Assets Other Goodwill
Measurement Stock Option Plans
Media Briefing Webcast 400
Media Contact
Media Contacts
Media Relations
Medications Alone
Medicines Malaria Venture
Medley Brazil
Meeting Committee
Meningitis Pneumonia Vaccines
Meningitis Program
Meningococcal Disease
Meningococcal Meningitis Major Public Health Problem Approximately 500000
Mercks Interest Merial
Merger Sanofi Group Synthélabo
Messer Griesheim Gmbh
Metabolic Disorders
Methionine Antitrust Litigation
Michel Labie
Micromet Inc
Milan 2005
Minimizing Toxicity
Minority Interests
Monoclonal Antibodies
Monoclonal Antibody Oncology
Moraxella Catarrhalis
Moreover People Europe United States Suffer Chronic Kidney
Motion Filed Preliminary Injunction Plavix Patent Infringement Case
Multaq Dronedarone
Multiple Sclerosis
Multiple Sclerosis Most Common Cause Disability Young Adults
Mycoplasma Pneumoniae
Mérieux Alliance
Nanchang Plants Expansion Project
Nasacort Patent Litigation
National Surgical Adjuvant Breast Bowel Project Nsabp Protocol
Nci Studies
Nearly Cumulative Synergies Delivered End 2005
Neisseria Meningitidis
Net Debt
Net Debt Currency
Net Debt Type Value Redemption
Net Financial Expense
Net Financial Income Expense
Net Income
Net Income Attributable Equity Holders
Net Income Attributable Minority Interests
Net Other Operating Income
Net Sales
Net Sales 110 Comparable Basis
Net Sales 128 6853m Comparable Basis Down Reported
Net Sales Business Segment
Net Sales Business Segment Human Vaccines
Net Sales Business Segment Pharmaceuticals
Net Sales Geographic Region
Net Sales Geographical Region
Net Sales Human Vaccines
Net Sales Product
Net Sales Product -reported-basis Growth
New 2005 Stock Subscription Option Plan Granted Sanofi-aventis
New 2006 Stock Subscription Option Plan Granted Sanofi-aventis
New Anti-arrhythmic Drug Approved European Union Last
New Committees 2008
New England Journal Medicine
New Facility Increase Production Capacity
New Formulation Been Developed Aim Improving Vaccine Effectiveness
New Indication Enoxaparin Now Applicable Across Full Spectrum
New Interpretations
New Lantus Solostar Test Results Published
New Operating Models
New Organization Announced 2007
New Products Portfolio
New Rapid-acting Insulin Analog Now Available United States
New Solid Tumor Bite Antibody
New Standards Amendments Interpretations Applicable 2008
New Standards Interpretations Applicable 2006
New Standards Interpretations Applicable 2007
New Standards Interpretations Subsequent Application
New Tax Distribution Regime
New Vaccine Against Polio Decades Used Egypt Part
New Vaccine Targets
New York
New York 2005
Nicole Cranois
Notes Pro Forma Financial Information
Notes References
Notice General Shareholders Meetings
Notice Shareholders Meetings
Number Employees
Nutraceuticals Otc Division Australia
Obese Overweight Patients
Objective Definition Internal Control
Objectives Derivative Financial Instruments
Obligation Acquire Hoechst Aktiengesellschaft Shares
Obligations Directors
Observed Pro-arrhythmia
Observers Censeurs
Offer Listing Details
Offer Price
Olivier Charmeil
Olivier Jacquesson
Oncology Immunology
Oncology Very Ambitious Program Studies Accelerate Market Access
Ongoing Cost Adaptation Measures
Ongoing Transformation Sanofi-aventis
Only Extended-release Prescription Sleep Medication Indicated Induction Maintenance
Opening Organization Outside World
Operating Income
Operating Income Before Restructuring Impairment Ppe Intangibles Gains
Operating Income Before Restructuring Impairment Property Plant Equipment
Operating Income Current
Operating Leases
Operating Profit
Operating Results
Operational Foreign Exchange Derivatives
Operational Foreign Exchange Derivatives 2006
Operational Foreign Exchange Derivatives 2008
Operational Foreign Exchange Risk
Operations Board Directors
Operations Committee
Opticlick Patent Litigation
Opticlik Patent Litigation
Option Additional Doses
Options Purchase Group Shares
Options Subscribe Group Shares
Organization Adjustments
Organizational Audits Conducted Pharmaceuticals Operations Directorate
Organizational Structure
Organizing Group
Other Adjustments
Other Blood Products Litigation
Other Business Combinations
Other Current Assets
Other Current Operating Income
Other Current Operating Income Expenses
Other Developments
Other Foreign Exchange Risks
Other Highlights Half 2005 Included
Other Intangible Assets
Other Legal Matters Adverse Outcomes Changes Law Material
Other Legal Matters Adverse Outcomes Material Effect Business
Other Litigation Arbitration
Other Long-term Investments
Other Long-term Obligations
Other Operating Income Expense
Other Operating Income Expenses
Other Participants
Other Pharmaceutical Products
Other Products
Other Reclassifications
Other Required Applicable Law Anofi-aventis Not Undertake
Other Required Applicable Law Sanofi-aventis Not Undertake Obligation
Other Revenues
Other Segment Information
Other Serious Infectious Diseases
Other Significant Changes 2004
Other Significant Events
Other Standards
Other Study Results Protocol
Other Vaccines
Outlook 2005
Ovarian Cancer
Ovarian Study
Over Euros Invested
Over People Worldwide Suffer Alzheimers Disease
Over Polio-free Countries Using Ipv
Ownership Securities
Ownership Shares Non-french Persons
Oxford Biomedica
Pandemic Influenza
Pandemic Influenza Overview
Pandemic Influenza Vaccine
Panenza Humenza
Paragraph Commercial Code
Paris 2004
Paris 2005
Paris 2006
Paris 2007
Paris 22nd 2006
Paris France 2005
Paris France 2006
Paris France 2006 Apotex Corp Announced Was Launching
Paris France 2007
Paris France 2007 8211
Paris France 2008 Sanofi-aventis Announced Chris Viehbacher Taken
Paris France Geneva Switzerland 2005
Paris France Jerusalem Israel 2007
Paris France New York 2006
Paris France New York Toronto 2006
Paris France Oxford 2007
Paris France Princeton 2006
Paris France Princeton Aug 2006
Paris France Princeton New Jersey 2006
Paris France San Antonio Usa 2006
Paris France Septembre 2008
Paris France Tarrytown 2007
Paris France Tokyo Japan 2007
Paris France-july 2008- Sanofi-aventis Announces Today Returning Territory
Paris New York 2005
Paris San Antonio 8th 2005
Paris Tokyo- 2005
Participating Shares
Participating Shares Series
Partnerships Access Medicines
Past Decade Lot Research Been Conducted Find Alternative
Patent Infringement Case
Patent Litigation
Patent Protection
Patents Infringed Infringe Others
Patients Atrial Fibrillation
Patients Atrial Fibrillation Flutter
Patients Treated Insulin
Paying-up Libération Shares
Pci-extract Timi Study
Pediar Infect Dis
Pediatric Adolescent Adult Booster Combination Vaccines
Pediatric Combination Adolescent Adult Booster Vaccines
Pediatric Combination Polio Vaccines
Pediatric Combination Poliomyelitis Polio Vaccines
Pediatric Extension
Pensions Post Retirement Benefits
Pensions Post-retirement Benefits
Pensions Unrecognized Actuarial Gains Losses
Per Share Paid 21st
Percutaneous Coronary Intervention Pci
Performance Buoyed Key Growth Drivers
Periods Exclude Impact Exchange Rates Recalculating Sales Earlier
Persons Holding Adss Rather Shares Difficulty Exercising Certain
Pfizer Disclosure Notice
Pfizer Disclosure Notice Information Contained Release 2005 Assumes
Phage Display Technology
Pharmaceutical Activity
Pharmaceutical Industry Antitrust Litigation
Pharmaceutical Operations Europe Excluding France Germany
Pharmaceutical Research Development
Phase Development Program Aflibercept
Phase Studies Aflibercept Combination Chemotherapy
Phase Studies Aflibercept Symptomatic Malignant Ascites Sma
Phase Study
Phase Study Single-agent Aflibercept Advanced Ovarian Cancer
Phase Trial Trovax High-dose Interleukin-2 Metastatic Renal Cancer
Phase Trial Trovax Interferon-alpha Metastatic Renal Cancer
Phase Trial Trovax Low-dose Interleukin-2 Metastatic Renal Cancer
Philippe Barquet 670486128
Philippe Fauchet
Philippe Peyre
Pi3k Inhibitors
Pierre Chancel
Planning Developing Strategy
Plavix Antitrust Claim
Plavix Consumer Fraud Claims
Plavix Europe
Plavix Iscover
Plavix Litigation
Plavix Litigation Settlement Fails Receive Antitrust Clearance States
Plavix Patent
Plavix Patent Infringement Case
Plavix Patent Litigation
Plavix Product Litigation
Plavix Recovers Position Full Impact Expected
Pneumococcal Program
Pneumococcal Vaccine Program
Polio Haemophilus Influenzae Type Hib
Positive Phase Iib Results Products
Postprandial Glucose Control Apidra
Potentially Maximize Efficacy
Pre-acquisition Tax Contingencies
Preclinical Studies
Preemptive Rights
Preferential Subscription Rights
Preliminary Injunction Ordered Plavix Patent Infringement Case Apotex
Presentation Alliance Agreements Bms
Presentation Consolidated Financial Statements
Presentation Differences
Presentation Financial Other Information
Presentation Net Sales
Presented Comparability Purposes Though Offer Aventis Transactions Described
Press Release
Press Release Contains Forward-looking Statements Defined Private Securities
Press Release Only Communicated Persons United Kingdom Circumstances
Prevalence Diabetes Increasing Worldwide Number Diabetics Reach 330
Prevention Venous Thrombo-embolic Events Remains Major Public Health
Pricing Reimbursement
Pricing Volume Other Restrictions
Principal Accountants Fees Services
Principal Amount Eur
Principal Associates
Principal Financing Transactions
Principal Partnerships
Principal Pharmaceutical Products
Principal Products
Principal Vaccines Products
Principles Internal Control
Pro Forma
Pro Forma Amortization Impairment Intangibles
Pro Forma Combined Developed Sales
Pro Forma Combined Net Sales
Pro Forma Combined Net Sales Business Segment
Pro Forma Combined Net Sales Geographical Region
Pro Forma Combined Net Sales Top Products
Pro Forma Exceptional
Pro Forma Goodwill Amortization
Pro Forma Gross Profit
Pro Forma Income Equity Investees Net
Pro Forma Income Taxes
Pro Forma Information
Pro Forma Minority Interests
Pro Forma Net Financial Income Expense
Pro Forma Net Income
Pro Forma Net Sales
Pro Forma Net Sales Geographic Area
Pro Forma Net Sales Human Vaccines
Pro Forma Statement Income
Procedures Associated Other Executive Operational Support Processes
Procedures Supporting Preparation Chairmans Report
Procter Gamble Pharmaceuticals
Procter Gamble Pharmaceuticals Alliance
Produce Vaccines Meeting Highest Quality Standards
Product Liability Claims Adversely Affect Business Operating Results
Product Liability Claims Adversely Affect Business Results Operations
Product Overview
Production Raw Materials
Products Committee
Profit-sharing Schemes
Proforma Combined Net Sales Geographical Region
Proforma Statement Income
Progress 2005
Project Boost Innovation
Project Funding
Project Highlights
Property Plant Equipment
Proportionately-consolidated Companies
Prostate Cancer
Protecting Safeguarding
Protection Against Meningococcal Infection
Provided Comparative Purposes Presented Though Offer Aventis Other
Provisions Other Liabilities
Provisions Pensions Other Long-term Benefits
Proxies Votes Mail
Pseudomembranous Colitis Been Reported Nearly Antibacterial Agents Including
Public Accounting Firms
Publication Clinical Trial Results
Published Information Review Committee
Purchase Accounting
Purchase Accounting Effects Primarily Acquisition Aventis 2004
Purchase Own Shares
Purchases Equity Securities Issuer Affiliated Purchasers
Purposes Share Repurchase Programs
Pursued Transformation Strategy Reinforcing Platforms Growth Forging Ahead
Questions Answers
Rabies Vaccine
Ral Treatment
Ramipril Canada
Ramipril Canada Patent Litigation
Read Important Information End Press Release
Receive Plavix Clopidogrel Bisulfate
Receive Plavix Clopidogrel Hydrogensulfate
Recent Accounting Pronouncements
Recent Events
Recent Events Associated Offers Aventis Hoechst Shares
Reconciliation 2004 Consolidated Net Sales Pro Forma
Reconciliation 2005 First-half Reported Net Sales Comparable
Reconciliation 2006 First-half Reported Net Sales Comparable
Reconciliation 2007 First-half Reported Net Sales Comparable
Reconciliation 2009 First-half Reported Net Sales Constant Exchange
Reconciliation Carrying Amount Value Redemption
Reconciliation Consolidated Income Statement Adjusted
Reconciliation Consolidated Net Income Adjusted
Reconciliation Consolidated Net Income Attributable Equity Holders Adjusted
Reconciliation First-half Developed Sales 2005 2004
Reconciliation Net Income Adjusted
Reconciliation Net Income Attributable Equity Holders Adjusted
Recorded Video Webcast Presentations Available
Recurrent Major Depression
Redemption Shares
Refer Change Sales Comparable Basis Mean Exclude Impact
Refinancing Carried Out 2005
Regarding Zimulti Rimonabant
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Inc
Regenerons Velocisuite Technologies
Registered Capital
Registered Office
Regulatory Environment Increasingly Challenging Pharmaceutical Industry
Regulatory Exclusivity
Related Party Transactions
Related-party Transactions
Rely Parties Manufacture Supply Substantial Portion Raw Materials
Rely Parties Marketing Some Products
Rely Parties Marketing Some Products Act Ways Harm
Remain Open Until 2009
Renal Cancer
Renal Cell Carcinoma
Report Chairman Board Directors Preparation Organization Work Internal
Report Independent Registered Public Accounting Firms
Reporting Obligations
Required Reports Pursuant Securities Exchange Act 1934
Requirements Holdings Exceeding Certain Percentages
Research Alliance
Research Development
Research Development Costs Acquired Separately
Research Development Expenses
Research Development Process Lengthy Carries Substantial Risk Product
Research Development Production Activities
Research Development Sites
Research Development Sites Pharmaceutical Activity
Research Development Update
Resolution Plavix Litigation
Respectively Full-year Adjusted Net Income 2005 Was
Respiratory Allergy
Responds Fda Recommendation Influenza Virus Strain Change Supplement
Response Even Those Over Age
Response Global Health Needs Dengue Vaccine
Restructuring Costs
Restructuring Provisions
Result Intensive Development Testing Diabetes Patients Doctors Nurses
Result New Information Future Events Developments
Result Over Intensive Development Testing Designed Pen Input
Results Confirm 2006 Full-year Guidance See Page
Results Guidance
Results Presented Adas Annual Scientific Sessions
Revenue Recognition-bms Alliance
Reversal Impairment Loss
Review Portfolio
Rhodia Equity Swap
Rhodia Shareholder Litigation
Right Access Representation
Right Access-representation
Rights Obligations Attached Each Share
Rilutek Litigation
Rilutek Patent Litigation
Rimonabant Acomplia
Rimonabant Usa Update
Rio-diabetes Study Showed Rimonabant 20mg Significantly Improved Weight
Rio-diabetes Trial
Risk Factors
Risks Handling Hazardous Materials Adversely Affect Operating Results
Risks Handling Hazardous Materials Adversely Affect Results Operations
Role Board Directors
Role Internal Control Assessment Department
Roles Powers Chairman Chief Executive Officer
Russia National Project Health
Sabril Litigation
Sabril Litigation Anti-epilepsy
Safety Efficacy Data Presented 2009 Ectrims
Safety Information
Safety Information Influenza H1n1 2009 Monovalent Vaccine
Safety Tolerability
Sales Active Ingredient American Joint Venture Managed Bms
Sales Shares Cause Market Price Adss Decline
Sales Shares Eligible Sale Near Future Cause Market
Salk Institute Biological Studies
San Diego 2005
Sanofi Aventis Pfizer Seek Approval Market Exubera United
Sanofi Pasteur
Sanofi Pasteur Begins Shipping Adacel Vaccine Combined Protection
Sanofi Pasteur Blood Products Litigation
Sanofi Pasteur China
Sanofi Pasteur Clinical Trial Design
Sanofi Pasteur Crucell Exclusive Agreement
Sanofi Pasteur Dengue Vaccine Global Clinical Study Program
Sanofi Pasteur Hepatitis Vaccine Litigation
Sanofi Pasteur Inc Thimerosal Litigation
Sanofi Pasteur Influenza Vaccine Production
Sanofi Pasteur Mmr Vaccine Litigation
Sanofi Pasteur Pandemic Preparedness
Sanofi Pasteur Pipeline
Sanofi Pasteur Sites
Sanofi Pasteur Thimerosal Litigation
Sanofi-aventis 2005 First-half Consolidated Income Statement
Sanofi-aventis Acquire Fovea French Biopharmaceutical Ophthalmology
Sanofi-aventis Acquires 24876 Zentiva
Sanofi-aventis Also Excludes Integration Restructuring Costs Associated Transaction
Sanofi-aventis Brazil
Sanofi-aventis Cardiology Thrombosis
Sanofi-aventis China
Sanofi-aventis Committed Working Diabetes Community Develop New Technologies
Sanofi-aventis Concludes Euro10 Medium-term Credit Agreements Banks Refinance
Sanofi-aventis Delivers 2008 Results Above Guidance
Sanofi-aventis Excludes Adjusted Net Income Restructuring Cost Associated
Sanofi-aventis Forward Looking Statements
Sanofi-aventis Forward-looking Statements
Sanofi-aventis Gains Market Share
Sanofi-aventis Group
Sanofi-aventis Group Conducts Business Through Affiliates Sanofi-synthelabo Inc
Sanofi-aventis Group Subsidiaries United States Include Sanofi-synthelabo Inc
Sanofi-aventis Mexico
Sanofi-aventis Oncology Target Cancer Commitment Action
Sanofi-aventis Parent Financial Statements 2006 French Gaap
Sanofi-aventis Parent Financial Statements Half 2005 French Gaap
Sanofi-aventis Partnership Fighting Against Neglected Diseases
Sanofi-aventis Pen Portfolio
Sanofi-aventis Pro Forma Income Statement 2004
Sanofi-aventis Research Development Achievements 2007
Sanofi-aventis Research Development Achievements 2008
Sanofi-aventis Research Development Diabetes
Sanofi-aventis Scientific Medical Affairs Achievements 2004
Sanofi-aventis Scientific Medical Affairs Achievements 2005
Sanofi-aventis Scientific Medical Affairs Achievements 2006
Sanofi-aventis Simplified Consolidated Balance Sheet
Sanofi-aventis Simplified Statement Cash Flows
Sanofi-aventis Statement
Sanofi-aventis Subsidiaries United States Include Sanofi-synthelabo Inc Aventis
Sanofi-aventis Sues Novopharm Patent Infringement Canada
Sanofi-aventis Transformation Program
Sanofi-aventiss Largest Shareholders Own Significant Percentage Enlarged Share
Schizophrenia Serious Psychiatric Condition Affecting Around Adult Population
Scope Ims Developed Sales Includes
Scope Internal Control
Searching Discovering Developing Registering New Products
Seasonal Influenza Overview
Seasonal Pandemic Influenza Vaccines
Seasonal Trends
Securities Offered Not Been Registered Act 1933 Amended
Securities Registered Pursuant Act
See Adverse Reactions
See Appendix Definitions Financial Indicators Page Details Selected
See Appendix Geographical Split Consolidated Net Sales Product
See Warnings
Segmental Analysis
Selected Exchange Rate Information
Selected Refer Appendix
Selected See Appendix
Selling General Expenses
Senior Management
Senior Vice President Audit Internal Control Assessment
Senior Vice President Business Development
Senior Vice President Chief Financial Officer
Senior Vice President Chief Medical Officer
Senior Vice President Communications Institutional Professional Relations
Senior Vice President Corporate Affairs
Senior Vice President Corporate Human Resources
Senior Vice President Global Marketing
Senior Vice President Global Marketing Access
Senior Vice President Human Resources Since 2008
Senior Vice President Industrial Affairs
Senior Vice President Industrial Affairs Since 2008
Senior Vice President International Development
Senior Vice President Legal Affairs General Counsel
Senior Vice President Pharmaceutical Operations Asia Pacific
Senior Vice President Pharmaceutical Operations Asia Pacific Japan
Senior Vice President Pharmaceutical Operations Europe Canada Excluding
Senior Vice President Pharmaceutical Operations France
Senior Vice President Pharmaceutical Operations Intercontinental
Senior Vice President Pharmaceutical Operations United States
Senior Vice President Research Development
Senior Vice President Vaccines
Serge Weinberg
Series Participating Shares
Shanghai Institutes Biological Sciences Sibs
Share Buyback Program
Share Capital
Share Issue Reserved Employees
Share Ownership
Share Profit Associates
Share Profit Loss Associates
Share Profits Associates
Share Repurchase Program
Share Repurchase Program Dividend
Share Repurchase Programs
Share Warrants
Share-based Payment
Shareholders Agreement
Shareholders Equity
Shares Adss
Shares Eligible Future Sale
Shares Owned Members Board Directors
Shares Owned Members Board Directors Executive Committee
Shares Owned Members Board Directors Senior Management
Sharp Rise Proposed Dividend
Shipment Fluzone Influenza Virus Vaccine Market Begins-
Short-term Debt Current Portion Long-term
Sickness Fexinidazole
Significant Acquisitions
Significant Changes
Significant Changes 2002
Significant Changes 2003
Significant Changes 2005
Significant Changes 2005 2006
Significant Changes Half 2005
Significant Divestments
Significant Post Balance Sheet Events
Significant Progress Pipeline
Signing Take Place Franco-russian Intergovernmental Seminar
Simplified Consolidated Balance Sheet
Simplified Consolidated Statement Cash Flows
Simplifying Administration Acute Coronary Syndrome Patients
Sleeping Sickness Human African Trypanosomiasis Hat
Slowdown Global Economic Growth Negative Consequences Business
Social Charter
Société Anonyme Conseil Dadministration
Solid Quarterly Results 2009 Full-year Guidance Updated
Solostar Patent Litigation
Some 300 People Suffer Dyslipidemia Largest Industrialized Countries
Sorbates Industry Investigation
Source Sdi 2005 Update
Sources Revenues Expenses
Specialist Committees
Spirits Study
Split Business Segment
Split Net Sales
Ssr 591813 Smoking Cessation
Stake Regeneron Approximately
Standards Amendments Applicable Consolidated Financial Statements Sanofi-aventis
Standards Amendments Not Apply Consolidated Financial Statements Sanofi-aventis
Staphylococcus Aureus
State Local Taxes
Statement Corporate Governance Required 303a-11 New York Stock
Statement Corporate Governance Required Rule 303a11 New York
Statements Cautionary Factors
Statistical Analysis
Status Owner
Statutory Auditors
Statutory Profit-sharing Scheme Participation Des Salariés Aux Résultats
Statutory Scheme Participation Des Salariés Aux Résultats Lentreprise
Stemi Acute Coronary Syndrome
Stilnox Ambien Myslee
Stilnox Zolpidem Product Litigation
Stock Market Risk
Stock Option Plans
Stock Option Plans Share Warrants
Stock Options
Stock Options Exercised Directors Employees
Stock Options Held Jean-françois Dehecq
Stock Options Warrants
Stock Purchase Option Plans
Stock Subscription Option Plan Granted Sanofi-aventis
Stock Subscription Option Plans
Stock-based Compensation
Strategy Committee
Strengthen Creativity Innovation
Streptococcus Pneumoniae
Strong Cash Flow Operating Activities Half 2009
Strong Growth 257 2005 Adjusted Eps Nearly Synergies
Studies Support Safety Immunogenicity
Study Design
Study Designs
Study Findings
Study Results
Study Suggests Rimonabant Achieve Improvement Blood Glucose Added
Subject Various Risks
Summarized Financial Information Related Equity Investees
Summary Not Constitute Legal Tax Advice Holders Consult
Summary Selected Financial Data
Summary Selected Historical Consolidated Financial Data Sanofi-aventis Aventis
Summary Stock Option Plans
Sunday 500 515 Hall Oral Presentation
Survival Rates Advanced Head Neck Cancer Historically Been
Survival Update Prognostic Factor Analysis Oxaliplatin Irinotecan Iri
Sustainable Development Health Safety Environment Hse
Sustained Sales Growth
Swiftwater Lyon France 2005
Swiftwater Lyon France 2006
Swiftwater Lyon France 2007
Symbion Consumer
Symptomatic Malignant Ascites
Table Below Shows Key First-half Figures
Targeted Partnerships Support Development Innovative Products
Tax 325 Study
Tax 327 Study
Tax Sale Other Disposition
Tax Sale Other Disposition Including Redemption
Taxation Annual Payments
Taxation Annual Payments Reorganization Payment
Taxation Dividends
Taxation Redemption
Taxotere Now Approved Cancer Types Japan-
Taxotere Patent Litigation
Taxotere Receives Fda Approval Treatment Patients Head Neck
Team Research Worlds Largest Vaccine Manufacturers Combination Parties
Teva Pharmaceutical Industries
Teva Pharmaceuticals
Teva Safe Harbor Statement Private Securities Litigation Reform
Thailand Scientific Milestone
Then Named Gérard Fur Chief Executive Officer Jean-françois
They Colleagues Study Rather Research Subjects
Thrombosis Diabetes Cardiovascular Unique Portfolio Most Promising Industry
Thursday 2007
Time Compared Placebo
Timing Payment
Timothy Rothwell
Tokyo Japan Paris France 2006
Top Products
Trading Eurolist Market
Trading Euronext Paris Market
Trading Own Shares
Trading Practices Own Shares
Transactions Associates
Transactions Directors Materially Interested
Transactions Shares Members Board Directors
Transfer Rights Exubera Interest Diabel
Transfer Shares
Transformation Sanofi-aventis
Transforming Sanofi-aventis Diversified Global Leader Healthcare
Transition Ifrs
Travel Endemic Measles Mumps Rubella Mmr Vaccines
Travel Endemic Vaccines
Treasury Shares
Treat Type Diabetes
Treatment Legacy Bsas
Treatment Milestone Payments Licensing Agreements
Treatments People Living Type Diabetes
Trial Demonstrates Optimal Therapeutic Index Patients Tch Did
Trials Vte Prevention Atrial Fibrillation Patients
Triple Negative Breast Cancer Tnbc
Tritace Triatec Delix Altace
Types Stock Options
Ucb Forward-looking Statement
Unable Protect Proprietary Rights Compete Effectively Operate Profitably
Unable Protect Proprietary Rights Fail Compete Effectively Operate
Unable Protect Proprietary Rights Not Compete Effectively Operate
United Kingdom
United States
University California Berkeley
Unless Otherwise Indicated Growth Figures Press Release Comparable
Unless Otherwise Indicated Sales Growth Figures Press Release
Update Caption Armour Blood Products Litigation D201 Consolidated
Update Caption Government Investigations Pricing Marketing Practices D201
Update Caption Lovenox Patent Litigation D22b Consolidated Financial
Update Caption Plavix Patent Litigation D22b Consolidated Financial
Update Caption Ramipiril Canada D201 Consolidated Financial Statements
Update Caption Rhodia D201 Consolidated Financial Statements Included
Update Caption Sanofi Pasteur Inc Thimerosal Litigation D22a
Update Caption Solostar Patent Litigation D22b Consolidated Financial
Vaccine Combined Protection Against Tetanus Diphtheria Pertussis
Vaccine Government
Vaccine Shan5 Dtp Hib Hepb
Vaccines Clinical Results Meet Major Public Health Needs
Vaccines Products
Vaccines Research Development
Valuation Methods
Van Gogh Dvt Trials
Van Gogh Extension Trials
Various Cancer Types Stages Disease Data Suggest Product
Vegf Trap Clinical Development Program Oncology
Vegf Trap Represent New Treatment Regimen Seriously Ill
Venous Thromboembolism Vte
Vice President Chemistry
Vienna Austria 2006
Vitamin Antitrust Litigation
Voluntary Scheme Intéressement Des Salariés
Votes Required Shareholder Action
Voting Rights
Wacker Chemie
Was Prepared Basis Following Principles
Wayne Pisano
Wealth Tax
Well-controlled Patients Derive Benefit Switch Lantus
Wellstat Therapeutics
West Nile Virus Infections
While Adding Late Stage Development Portfolio
Wiftwater Lyon France 2006
Working Capital Needs Increased 1281163 Period Compared 1281076
World Heart Federation
Worlds Largest Diabetes Genotyping Project
Worldwide Comparable-basis Sales Plavix Aprovel 2007 2006 Split
Worldwide Comparable-basis Sales Plavix Aprovel 2008 2007 Split
Worldwide Presence Aprovel Avapro Karvea
Worldwide Presence Plavix Aprovel
Worldwide Presence Plavix Iscover
Worldwide Presence Product
Xaliproden Severe Peripheral Sensory Neuropathy Psn Induced Chemotherapy
Xatral Patent Litigation
Xatral Uroxatral
Xl147 Xl765
Xyzal New Treatment Option Todays Challenging Allergy Environment
Xyzal Tablets Anda
Yves Rocher
Zentiva Approximately 128
Zentiva Offer
Zentiva Shareholders Until 2009 Tender Shares
Zimulti Acomplia Rimonabant Class Action
Zimulti Rimonabant Class Action
Skip the spreadsheet. Track your investments automatically.
Start now
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012.
Use of this site is subject to express
Terms of Service
Privacy Policy
, and
. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by
. See
data providers
for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Get involved
Licensing & Partnerships
Blogger Tools


text:
Snapchat Challenge: Are you #TeamHwaShin or #TeamJungWon in Jealousy Incarnate?
Once again, second lead syndrome has come to rip my heart out, this time in Jealousy Incarnate! But at the same time, I can't help but love and feel sorry for the first lead at this point, too. I'm so torn! So I need your opinion: Are you #TeamHwaShin or #TeamJungWon?
I just put the question out over DramaFever's official Snapchat account, username @dramafever, so please hop on Snapchat and send me a message telling me which guy you hope Na Ri ends up with and why.
Here is our Snap code:
The responses are already coming in!
I'm noticing a major trend here!
If you don't have Snapchat, then please leave your comment below!
And be sure to check out Jealousy Incarnate for one killer love triangle and second lead syndrome galore!
Jealousy Incarnate
Starring Jo Jung Suk and Gong Hyo JinAdd to Queue Remove from Queue Watch Now